Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma - Concepedia

Concepedia

Publication | Open Access

Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma

DOI Full Paper Access

439

Citations

18

References

2005

Year

Mathias Rummel, S. Al-Batran, Soo-Z. Kim, Manfred Welslau, Ralf Hecker, Dorothea Kofahl-Krause, Klaus-M. Josten, Heinz Dürk, A. Rost, Michael Neise,

Journal of Clinical Oncology

Abstract

These results demonstrate that the BR combination is a highly active regimen in the treatment of low-grade lymphomas and mantle cell lymphomas.

References

	Year	Citations
A Predictive Model for Aggressive Non-Hodgkin's Lymphoma New England Journal of Medicine	1993	4.9K
A predictive model for aggressive non-Hodgkin's lymphoma Margaret A. Shipp, David P. Harrington, J R Anderson, Lymphoid NeoplasiaAggressive Non-hodgkinMedicinePathologyLymphatic Disease	1993	3.5K
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 ME Reff, K Carner, KS Chambers, Blood	1994	1.9K
IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma David G. Maloney, Antonio J Grillo-López, Christine A. White, Blood	1997	1.7K
Follicular Lymphoma International Prognostic Index Blood	2004	1.5K
Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy M. S. Czuczman, A.J. Grillo-López, Christine A. White, Journal of Clinical Oncology	1999	855
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group Roswitha Forstpointner Blood	2004	579
Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG) Georg Lenz, Martin Dreyling, Eva Hoster, Journal of Clinical Oncology	2005	573
Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic Drugs Aïcha Demidem, Tammy Lam, Steve Alas, Cancer Biotherapy and Radiopharmaceuticals	1997	397
Rituximab and CHOP Induction Therapy for Newly Diagnosed Mantle-Cell Lymphoma: Molecular Complete Responses Are Not Predictive of Progression-Free Survival Orion M. Howard, John G. Gribben, Donna Neuberg, Journal of Clinical Oncology	2002	347

Page 1